All In Biotech

NDA 200533 · Collegium Pharm INC

Nucynta Er

Tapentadol Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Aug 25, 2011

Approved uses

3

Original approval plus efficacy supplements

Registered trials

73

35 Phase 3, 1 recruiting

FAERS reports

33,575

30,074 serious, 20,764 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF TAPENTADOL EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of tapentadol extended-release tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death assess, each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of tapentadol extended-release tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of tapentadol extended-release tablets are essential. Instruct patients to swallow tapentadol extended-release tablets whole;...

What it is approved for

From the label in effect Feb 26, 2026.

Tapentadol extended-release tablets are indicated for the management of: Severe and persistent pain in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ] , reserve tapentadol extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. tapentadol extended-release tablets are not indicated as an as-needed (prn) analgesic. Tapentadol extended-release tablet is an opioid agonist indicated for the management of: severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. ( 1 ) severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. ( 1 ) Limitations of Use ( 1 ) Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death...

Mechanism: Tapentadol is a centrally-acting synthetic analgesic. The exact mechanism of action is unknown. Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is a mu-opioid receptor (MOR) agonist and a norepinephrine reuptake inhibitor (NRI). Analgesia in animal models is derived from both of these properties.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • NUCYNTA ER · TAPENTADOL HYDROCHLORIDE EQ 200MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • NUCYNTA ER · TAPENTADOL HYDROCHLORIDE EQ 100MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • NUCYNTA ER · TAPENTADOL HYDROCHLORIDE EQ 250MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • NUCYNTA ER · TAPENTADOL HYDROCHLORIDE EQ 150MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • NUCYNTA ER · TAPENTADOL HYDROCHLORIDE EQ 50MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tapentadol" as an intervention, any sponsor and status, largest first.

All 73 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death11,645
  • toxicity to various agents9,959
  • overdose5,890
  • drug abuse1,553
  • drug dependence1,073
  • drug ineffective1,039
  • drug withdrawal syndrome neonatal944
  • pain767
  • nausea735
  • accidental overdose721
  • fatigue457
  • headache418

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20082
200998
2010155
2011350
2012418
2013377
2014364
20151,376
20161,060
20172,490
201821,688
2019848
2020729
2021705
2022593
2023559
2024706
2025546
2026510

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nucynta ER (Tapentadol HCl)

2024 spending

$47.7M

Beneficiaries

5,370

40,396 claims

Per beneficiary

$8,890

$20.74 per unit

View as table
YearSpending
2020$65,282,808
2021$63,697,831
2022$66,832,483
2023$53,178,879
2024$47,741,763

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 133 on PubMed

Sponsor: Collegium Pharm INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.